The series of direct-to-consumer oncology advertisements targeting patients with advanced kidney cancer (renal cell carcinoma) and their caregivers.  

With Celgene and other acquisition costs in the rearview, Bristol Myers Squibb returned to profitability with a vengeance in 2021.

Today, the company announced that Part A of the Phase III CheckMate -914 which evaluated the two drugs in combination as an adjuvant treatment for localized renal cell carcinoma (RCC) failed to hit the primary endpoint.

The long weekend saw three established drugs developed by Bristol Myers Squibb, Novartis, and Roche score new approvals from the U.S. Food and Drug Administration.